INDEMNITY AGREEMENTIndemnification Agreement • December 31st, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , , is made by and between REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • December 31st, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 20, 2011 and is entered into by and between REVANCE THERAPEUTICS, INC., a Delaware corporation (hereinafter referred to as the “Borrower”) and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”).
LOAN AND LEASE AGREEMENT Dated as of December 20, 2013 the “Effective Date” by and between ESSEX CAPITAL CORPORATION as “Essex” and REVANCE THERAPEUTICS, INC. as “Company” TOTAL CREDIT AMOUNT: Up to $10,800,000Loan and Lease Agreement • December 31st, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
Company wishes to acquire certain equipment. Essex is willing to finance that acquisition by lending money to Company to build out and install that equipment and, upon Company’s acceptance of the equipment, by purchasing that equipment and leasing it to Company. The information set forth above is subject to the terms and conditions set forth in the balance of this Agreement. The parties agree as follows:
AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • December 31st, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Amendment”) is made and entered into as of this 8th day of October, 2013 by and among REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”) and the undersigned parties named herein.
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • December 31st, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AND SUPPLY AGREEMENT (this “Agreement”) is made as of this 11 day of December, 2009 (the “Effective Date”) by and between Revance Therapeutics, Inc., having a principal place of business at 7555 Gateway Boulevard, Newark, CA 94560 (“Revance”) and Hospira Worldwide, Inc., having a principal place of business at 275 North Field Drive, Lake Forest, Illinois, 60045, (U.S.A.) (“Hospira”).
FIRST ADDENDUM TO LICENSE AND SERVICE AGREEMENTLicense and Service Agreement • December 31st, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST ADDENDUM (“First Addendum”), is made and entered into, effective as of April 21, 2009 (“First Addendum Date”), by and between Revance Therapeutics, Inc., having a principal place of business at 2400 Bayshore Parkway, Suite 100, Mountain View, CA 94043 (“Revance”) and List Biological Laboratories, Inc., having a principal place of business at 540 Division Street, Campbell, CA 95008 (“List”), (collectively, the “Parties” or individually, a “Party”).
LICENSE AND SERVICE AGREEMENTLicense and Service Agreement • December 31st, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
This License and Service Agreement (together with any Attachments hereto, the “Agreement”) is entered into as of February 8, 2007 (the “Effective Date”), by and between Revance Therapeutics, Inc., (“Revance”), a Delaware corporation, with its principal offices at 2400 Bayshore Parkway, Suite 100, Mountain View, CA 94043 and List Biological Laboratories, Inc., (“List”), a California corporation with its principal offices at 540 Division Street, Campbell, CA 95008. Revance and List are sometimes referred to herein individually as a “Party” and collectively as the “Parties”, and references to “Revance” and “List” shall include their respective Affiliates.
